TICKERNOMICS Sign up
Last Update: 2023-12-23 06:03:02
Immix Biopharma Inc. ( IMMX ) https://www.immixbio.com
7.14USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
IMMX
229.03%
SPY
30.72%
IMMX
0.00%
SPY
112.82%
IMMX
0.00%
SPY
201.04%
IMMX
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
122.80
103.22
0.30
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-8.68
-1.37
6.25
-23.31
0.00
-7.10
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
2.82
100.00
4.06
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
3.86
-96.54
-96.69
0.00
Other Earnings and Cash Flow Stats:
Immix Biopharma Inc. ( IMMX ) Net Income TTM ($MM) is -12.11
Immix Biopharma Inc. ( IMMX ) Operating Income TTM ($MM) is -12.37
Immix Biopharma Inc. ( IMMX ) Owners' Earnings Annual ($MM) is 0.00
Immix Biopharma Inc. ( IMMX ) Current Price to Owners' Earnings ratio is 0.00
Immix Biopharma Inc. ( IMMX ) EBITDA TTM ($MM) is -12.34
Immix Biopharma Inc. ( IMMX ) EBITDA Margin is 4.06%
Capital Allocation:
Immix Biopharma Inc. ( IMMX ) has paid 0.00 dividends per share and bought back -4.653582 million shares in the past 12 months
Immix Biopharma Inc. ( IMMX ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
Immix Biopharma Inc. ( IMMX ) Interest-bearing Debt ($MM) as of last quarter is 0
Immix Biopharma Inc. ( IMMX ) Annual Working Capital Investments ($MM) are -1
Immix Biopharma Inc. ( IMMX ) Book Value ($MM) as of last quarter is 19
Immix Biopharma Inc. ( IMMX ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Immix Biopharma Inc. ( IMMX ) has 19 million in cash on hand as of last quarter
Immix Biopharma Inc. ( IMMX ) has 2 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Immix Biopharma Inc. ( IMMX ) has 18 common shares outstanding as of last quarter
Immix Biopharma Inc. ( IMMX ) has 0 million USD of preferred stock value
Academic Scores:
Immix Biopharma Inc. ( IMMX ) Altman Z-Score is 6.04 as of last quarter
Immix Biopharma Inc. ( IMMX ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
Immix Biopharma Inc. ( IMMX ) largest shareholder is InterOcean Capital Group owning 15900 shares at 0.11 ($MM) value
Jason Hsu(an insider) Bought 31000 shares of Immix Biopharma Inc. ( IMMX ) for the amount of $144770.00 on 2023-12-11
60.14% of Immix Biopharma Inc. ( IMMX ) is held by insiders, and 1.94% is held by institutions
Immix Biopharma Inc. ( IMMX ) went public on 2021-12-16
Other Immix Biopharma Inc. ( IMMX ) financial metrics:
FCF:-10.55
Unlevered Free Cash Flow:0.00
EPS:-0.92
Operating Margin:2.82
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-86.59
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Immix Biopharma Inc. ( IMMX ) :
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.